The American Journal of Managed Care

PD-L1 Testing "Name of the Game" in First-Line Treatment of NSCLC

Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy. The ...
Cure Today

PD-L1 Testing in NSCLC

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer. Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we ...
Monthly Prescribing Reference

Keytruda, Tecentriq Labeling Updated With PD-L1 Testing Requirements

The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for ...
Business Insider

Roche gains CE label expansion for PD-L1 testing in lung and bladder cancers in markets where TECENTRIQ is approved

TUCSON, Ariz., Sept. 28, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the expanded use of the VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) and metastatic ...
The American Journal of Managed Care

Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC

Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 ...